Contract Immunoassay R&D for Early Cancer Detection Company

Biofortuna have signed a long-term contract to provide contract research and development to a leading early cancer detection company. This relationship will lead to the commercialisation of  an ELISA based oncology assay.

Biofortuna will be providing:

  • Design and development consultancy of immunoassay technologies.
  • Expertise in ELISA reaction stabilisation methods.
  • Full validation and verification testing.
  • Technology transfer of small scale manufacturing procedures to full-scale commercialisation manufacturing protocols.
  • A potential manufacturing partner with a thorough understanding of the underlying technologies.